Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
blood cancer
Pharma
Johnson & Johnson's Tecvayli struts its stuff as a monotherapy
In a multiple myeloma trial, Tecvayli cut the risk of disease progression or death by 71% over standard care in patients resistant to CD38 therapy.
Kevin Dunleavy
Jan 15, 2026 10:15am
Orca rides $250M funding wave toward cancer cell therapy launch
Jan 9, 2026 11:19am
FDA OKs Darzalex as 1st drug for smoldering multiple myeloma
Nov 6, 2025 4:27pm
J&J eyes earlier myeloma treatment with ph. 3 Tecvayli combo win
Oct 16, 2025 8:10am
AbbVie, BeOne end BTK inhibitor patent fight
Oct 2, 2025 10:29am
Trial results show value of Lilly's Jaypirca in front-line CLL
Sep 8, 2025 11:37am
